tiprankstipranks
Gilead Sciences (NASDAQ:GILD) Ticks Higher After Settling Patent Challenges
Market News

Gilead Sciences (NASDAQ:GILD) Ticks Higher After Settling Patent Challenges

Gilead Sciences (NASDAQ:GILD) shares are ticking upwards after the healthcare major disclosed it has resolved litigation and patent challenges with major generic manufacturers including Lupin, Apotex, Macleods Pharma, Cipla, and Hetero Labs.

The challenges were related to Gilead’s Descovy, Vemlidy, and Odefsey. Under the agreements, Gilead has granted a non-exclusive license in the U.S. to the generic manufacturers for patents related to tenofovir alafenamide (Descovy and Vemlidy) starting October 31, 2031, and for Odefsey starting January 31, 2032.

The development implies that generic developers will be able to bring versions of these drugs on the market only after 2031 and 2032.

Read full Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles